following an abbreviated submission
eltrombopag (Revolade®) is accepted for restricted use within NHS Scotland.
Indication under review: chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
SMC restriction: use in patients with severe symptomatic ITP or a high risk of bleeding.
Eltrombopag has previously been accepted for restricted use in adult patients with chronic immune (idiopathic) thrombocytopenic purpura. The license has been extended to include children from 1 year.
SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of eltrombopag. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
Download detailed advice61KB (PDF)
Medicine details
- Medicine name:
- eltrombopag (Revolade)
- SMC ID:
- 1206/17
- Indication:
- Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 16 January 2017